Product Detail

Icodextrin is one kind pharmaceutical raw material, obtained by hydrolysis and refining from natural starch. Its preparation, icodextrin peritoneal dialysate, is the first dialysate of a new type of penetrant for peritoneal dialysis patients. Its discharge volume during long-term indwelling peritoneal dialysis is larger than that of conventional 1.5% and 2.5% glucose dialysate. Dialysis patients have limited renal function, so the removal of fluid is the cornerstone of dialysis treatment. When using traditional glucose dialysate, more dialysate is absorbed into the blood flow rather than discharged through ultrafiltration, which reduces the dialysis effect.
Icodextrin peritoneal dialysate is suitable for daily single exchange of ambulatory peritoneal dialysis (CAPD) in patients with chronic renal failure for a long time (8-16 hours). It can also be used for the improvement of long-term indwelling ultrafiltration (compared with 4.5% glucose) and the clearance of inosine and urea nitrogen in patients with above average or high transport properties determined by peritoneal balance test.
The original research of icodextrin peritoneal dialysate is American Baxter, which has been listed in many countries. Guangzhou Baxter has applied for production in 2017 and will be approved in 2021.